New Active Substance Launches Declined Again In 2016
Executive Summary
2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.
You may also be interested in...
Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.
NEW ACTIVE SUBSTANCES: 2014 broke records for new drug launches
Pharma take a bow: in 2014 you launched a record number of new active substances in their first markets worldwide.
ESMO: Sanofi/Regeneron’s Latecomer Anti-PD-1 Libtayo Looking Likely In NSCLC
Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Need a specific report? 1000+ reports available
Buy Reports